论文部分内容阅读
本文报道38例患者从其HLA-相容性同胞接受骨髓移植。38例中,14例再生障碍性贫血(AA)、22例急性白血病(AL)和2例播散性恶性肿瘤。6例AA患者的中数生存期为20个月,14例AL患者的中数生存期为7个月,生存最长时间分别为3年和1年半。上述资料提示,这些患者中有部分已治愈。22例死亡患者中,13例罹患移植物抗宿主病(GVHD),5例有严重感染,2例白血病复发。12例患者是死于严重肝细胞疾病,此种并发症尚未受到其他作者重视。作者研究了死亡、GVHD与肝损伤之间的关系。这些患者在骨髓移植前肝功能正常,移植后生化异常通常先于GVHD的临床征象出现,因而可成为GVHD这种并发症的有效的早期标志。60%的患者的肝脏组
This article reports 38 patients who underwent bone marrow transplantation from their HLA-compatible siblings. Of the 38 patients, 14 had aplastic anemia (AA), 22 had acute leukemia (AL) and 2 had disseminated malignancies. The median survival for 6 patients with AA was 20 months, the median survival for 14 patients with AL was 7 months, and the longest survival time was 3 years and 1 year and a half, respectively. The above data suggest that some of these patients have been cured. Of the 22 deaths, 13 developed graft-versus-host disease (GVHD), 5 had severe infection, and 2 had recurrent leukemia. Twelve patients died of a serious hepatocellular disease, a complication that has not received the attention of other authors. The authors studied the relationship between death, GVHD and liver damage. These patients have normal liver function prior to bone marrow transplantation. Biochemical abnormalities usually occur prior to the clinical signs of GVHD after transplantation, and thus can be effective early markers of GVHD complications. 60% of patients with liver group